CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of an analysis from the National Data Registry in South Korea that evaluated the association between hemolysis and mortality in patients with paroxysmal nocturnal hemoglobinuria (PNH). Researchers also presented new data from the PNH Registry, a multi-center, multi-national, observational study of patients with PNH: one presentation examined patient-reported quality of life, hospitalizations, and missed work, while a second evaluated the incidence of blood transfusions in patients with and without bone marrow disorders (BMD). Researchers reported these results at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando.
